Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Identifieur interne : 002E82 ( Main/Exploration ); précédent : 002E81; suivant : 002E83Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Auteurs : Rosemary Barnes [Royaume-Uni] ; Stephanie Earnshaw [États-Unis] ; Raoul Herbrecht [France] ; Orla Morrissey [Australie] ; Monica Slavin [Australie] ; Eric Bow [Canada] ; Cheryl Mcdade [États-Unis] ; Claudie Charbonneau [France] ; David Weinstein [France] ; Michal Kantecki [France] ; Haran Schlamm [États-Unis] ; Johan Maertens [Belgique]Source :
- Clinical therapeutics [ 1879-114X ] ; 2015.
Descripteurs français
- KwdFr :
- Acide désoxycholique (usage thérapeutique), Acide désoxycholique (économie), Amphotéricine B (usage thérapeutique), Amphotéricine B (économie), Antifongiques (usage thérapeutique), Antifongiques (économie), Arbres de décision, Aspergillose (diagnostic), Aspergillose (traitement médicamenteux), Aspergillose (économie), Aspergillus (isolement et purification), Association médicamenteuse, Coûts des soins de santé, Humains, Lipopeptides, Mannanes (analyse), Neutropénie fébrile (microbiologie), Ressources en santé (utilisation), Ressources en santé (économie), Sujet immunodéprimé, Taux de survie, Voriconazole (usage thérapeutique), Voriconazole (économie), Échinocandines (usage thérapeutique), Échinocandines (économie), Économies.
- MESH :
- analyse : Mannanes.
- diagnostic : Aspergillose.
- isolement et purification : Aspergillus.
- microbiologie : Neutropénie fébrile.
- traitement médicamenteux : Aspergillose.
- usage thérapeutique : Acide désoxycholique, Amphotéricine B, Antifongiques, Voriconazole, Échinocandines.
- utilisation : Ressources en santé.
- économie : Acide désoxycholique, Amphotéricine B, Antifongiques, Aspergillose, Ressources en santé, Voriconazole, Échinocandines.
- Arbres de décision, Association médicamenteuse, Coûts des soins de santé, Humains, Lipopeptides, Sujet immunodéprimé, Taux de survie, Économies.
English descriptors
- KwdEn :
- Amphotericin B (economics), Amphotericin B (therapeutic use), Antifungal Agents (economics), Antifungal Agents (therapeutic use), Aspergillosis (diagnosis), Aspergillosis (drug therapy), Aspergillosis (economics), Aspergillus (isolation & purification), Cost Savings, Decision Trees, Deoxycholic Acid (economics), Deoxycholic Acid (therapeutic use), Drug Combinations, Echinocandins (economics), Echinocandins (therapeutic use), Febrile Neutropenia (microbiology), Health Care Costs, Health Resources (economics), Health Resources (utilization), Humans, Immunocompromised Host, Lipopeptides, Mannans (analysis), Survival Rate, Voriconazole (economics), Voriconazole (therapeutic use).
- MESH :
- chemical , analysis : Mannans.
- chemical , economics : Amphotericin B, Antifungal Agents, Deoxycholic Acid, Echinocandins, Voriconazole.
- chemical , therapeutic use : Amphotericin B, Antifungal Agents, Deoxycholic Acid, Echinocandins, Voriconazole.
- diagnosis : Aspergillosis.
- drug therapy : Aspergillosis.
- economics : Aspergillosis, Health Resources.
- isolation & purification : Aspergillus.
- microbiology : Febrile Neutropenia.
- utilization : Health Resources.
- Cost Savings, Decision Trees, Drug Combinations, Health Care Costs, Humans, Immunocompromised Host, Lipopeptides, Survival Rate.
Abstract
Patients with persistent or recurrent neutropenic fevers at risk of invasive fungal disease (IFD) are treated empirically with antifungal therapy (AFT). Early treatment using a diagnostic-driven (DD) strategy may reduce clinical and economic burdens. We compared costs and outcomes of both strategies from a UK perspective.
DOI: 10.1016/j.clinthera.2015.03.021
PubMed: 25891805
Affiliations:
- Australie, Belgique, Canada, France, Royaume-Uni, États-Unis
- Alsace (région administrative), Caroline du Nord, Grand Est, Manitoba, Victoria (État), État de New York, Île-de-France
- Melbourne, Paris, Strasbourg, Winnipeg
- Université de Melbourne, Université du Manitoba
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002D26
- to stream PubMed, to step Curation: 002C51
- to stream PubMed, to step Checkpoint: 002C51
- to stream Ncbi, to step Merge: 002481
- to stream Ncbi, to step Curation: 002481
- to stream Ncbi, to step Checkpoint: 002481
- to stream Main, to step Merge: 002E83
- to stream Main, to step Curation: 002E82
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.</title><author><name sortKey="Barnes, Rosemary" sort="Barnes, Rosemary" uniqKey="Barnes R" first="Rosemary" last="Barnes">Rosemary Barnes</name><affiliation wicri:level="1"><nlm:affiliation>Cardiff University, University Hospital of Wales, Cardiff, United Kingdom. Electronic address: barnesra@cf.ac.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cardiff University, University Hospital of Wales, Cardiff</wicri:regionArea><wicri:noRegion>Cardiff</wicri:noRegion></affiliation></author><author><name sortKey="Earnshaw, Stephanie" sort="Earnshaw, Stephanie" uniqKey="Earnshaw S" first="Stephanie" last="Earnshaw">Stephanie Earnshaw</name><affiliation wicri:level="2"><nlm:affiliation>RTI Health Solutions, Research Triangle Park, North Carolina, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>RTI Health Solutions, Research Triangle Park, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Herbrecht, Raoul" sort="Herbrecht, Raoul" uniqKey="Herbrecht R" first="Raoul" last="Herbrecht">Raoul Herbrecht</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital de Hautepierre, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital de Hautepierre, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Morrissey, Orla" sort="Morrissey, Orla" uniqKey="Morrissey O" first="Orla" last="Morrissey">Orla Morrissey</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Slavin, Monica" sort="Slavin, Monica" uniqKey="Slavin M" first="Monica" last="Slavin">Monica Slavin</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Bow, Eric" sort="Bow, Eric" uniqKey="Bow E" first="Eric" last="Bow">Eric Bow</name><affiliation wicri:level="4"><nlm:affiliation>CancerCare Manitoba and the University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>CancerCare Manitoba and the University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Mcdade, Cheryl" sort="Mcdade, Cheryl" uniqKey="Mcdade C" first="Cheryl" last="Mcdade">Cheryl Mcdade</name><affiliation wicri:level="2"><nlm:affiliation>RTI Health Solutions, Research Triangle Park, North Carolina, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>RTI Health Solutions, Research Triangle Park, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Charbonneau, Claudie" sort="Charbonneau, Claudie" uniqKey="Charbonneau C" first="Claudie" last="Charbonneau">Claudie Charbonneau</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer International Operations, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Weinstein, David" sort="Weinstein, David" uniqKey="Weinstein D" first="David" last="Weinstein">David Weinstein</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer International Operations, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Kantecki, Michal" sort="Kantecki, Michal" uniqKey="Kantecki M" first="Michal" last="Kantecki">Michal Kantecki</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer International Operations, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Schlamm, Haran" sort="Schlamm, Haran" uniqKey="Schlamm H" first="Haran" last="Schlamm">Haran Schlamm</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Inc, New York, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Inc, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Maertens, Johan" sort="Maertens, Johan" uniqKey="Maertens J" first="Johan" last="Maertens">Johan Maertens</name><affiliation wicri:level="1"><nlm:affiliation>Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25891805</idno><idno type="pmid">25891805</idno><idno type="doi">10.1016/j.clinthera.2015.03.021</idno><idno type="wicri:Area/PubMed/Corpus">002D26</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002D26</idno><idno type="wicri:Area/PubMed/Curation">002C51</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002C51</idno><idno type="wicri:Area/PubMed/Checkpoint">002C51</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C51</idno><idno type="wicri:Area/Ncbi/Merge">002481</idno><idno type="wicri:Area/Ncbi/Curation">002481</idno><idno type="wicri:Area/Ncbi/Checkpoint">002481</idno><idno type="wicri:Area/Main/Merge">002E83</idno><idno type="wicri:Area/Main/Curation">002E82</idno><idno type="wicri:Area/Main/Exploration">002E82</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.</title><author><name sortKey="Barnes, Rosemary" sort="Barnes, Rosemary" uniqKey="Barnes R" first="Rosemary" last="Barnes">Rosemary Barnes</name><affiliation wicri:level="1"><nlm:affiliation>Cardiff University, University Hospital of Wales, Cardiff, United Kingdom. Electronic address: barnesra@cf.ac.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cardiff University, University Hospital of Wales, Cardiff</wicri:regionArea><wicri:noRegion>Cardiff</wicri:noRegion></affiliation></author><author><name sortKey="Earnshaw, Stephanie" sort="Earnshaw, Stephanie" uniqKey="Earnshaw S" first="Stephanie" last="Earnshaw">Stephanie Earnshaw</name><affiliation wicri:level="2"><nlm:affiliation>RTI Health Solutions, Research Triangle Park, North Carolina, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>RTI Health Solutions, Research Triangle Park, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Herbrecht, Raoul" sort="Herbrecht, Raoul" uniqKey="Herbrecht R" first="Raoul" last="Herbrecht">Raoul Herbrecht</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital de Hautepierre, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital de Hautepierre, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Morrissey, Orla" sort="Morrissey, Orla" uniqKey="Morrissey O" first="Orla" last="Morrissey">Orla Morrissey</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Slavin, Monica" sort="Slavin, Monica" uniqKey="Slavin M" first="Monica" last="Slavin">Monica Slavin</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Bow, Eric" sort="Bow, Eric" uniqKey="Bow E" first="Eric" last="Bow">Eric Bow</name><affiliation wicri:level="4"><nlm:affiliation>CancerCare Manitoba and the University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>CancerCare Manitoba and the University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Mcdade, Cheryl" sort="Mcdade, Cheryl" uniqKey="Mcdade C" first="Cheryl" last="Mcdade">Cheryl Mcdade</name><affiliation wicri:level="2"><nlm:affiliation>RTI Health Solutions, Research Triangle Park, North Carolina, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>RTI Health Solutions, Research Triangle Park, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Charbonneau, Claudie" sort="Charbonneau, Claudie" uniqKey="Charbonneau C" first="Claudie" last="Charbonneau">Claudie Charbonneau</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer International Operations, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Weinstein, David" sort="Weinstein, David" uniqKey="Weinstein D" first="David" last="Weinstein">David Weinstein</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer International Operations, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Kantecki, Michal" sort="Kantecki, Michal" uniqKey="Kantecki M" first="Michal" last="Kantecki">Michal Kantecki</name><affiliation wicri:level="3"><nlm:affiliation>Pfizer International Operations, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Schlamm, Haran" sort="Schlamm, Haran" uniqKey="Schlamm H" first="Haran" last="Schlamm">Haran Schlamm</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Inc, New York, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Inc, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Maertens, Johan" sort="Maertens, Johan" uniqKey="Maertens J" first="Johan" last="Maertens">Johan Maertens</name><affiliation wicri:level="1"><nlm:affiliation>Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author></analytic><series><title level="j">Clinical therapeutics</title><idno type="eISSN">1879-114X</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amphotericin B (economics)</term><term>Amphotericin B (therapeutic use)</term><term>Antifungal Agents (economics)</term><term>Antifungal Agents (therapeutic use)</term><term>Aspergillosis (diagnosis)</term><term>Aspergillosis (drug therapy)</term><term>Aspergillosis (economics)</term><term>Aspergillus (isolation & purification)</term><term>Cost Savings</term><term>Decision Trees</term><term>Deoxycholic Acid (economics)</term><term>Deoxycholic Acid (therapeutic use)</term><term>Drug Combinations</term><term>Echinocandins (economics)</term><term>Echinocandins (therapeutic use)</term><term>Febrile Neutropenia (microbiology)</term><term>Health Care Costs</term><term>Health Resources (economics)</term><term>Health Resources (utilization)</term><term>Humans</term><term>Immunocompromised Host</term><term>Lipopeptides</term><term>Mannans (analysis)</term><term>Survival Rate</term><term>Voriconazole (economics)</term><term>Voriconazole (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acide désoxycholique (usage thérapeutique)</term><term>Acide désoxycholique (économie)</term><term>Amphotéricine B (usage thérapeutique)</term><term>Amphotéricine B (économie)</term><term>Antifongiques (usage thérapeutique)</term><term>Antifongiques (économie)</term><term>Arbres de décision</term><term>Aspergillose (diagnostic)</term><term>Aspergillose (traitement médicamenteux)</term><term>Aspergillose (économie)</term><term>Aspergillus (isolement et purification)</term><term>Association médicamenteuse</term><term>Coûts des soins de santé</term><term>Humains</term><term>Lipopeptides</term><term>Mannanes (analyse)</term><term>Neutropénie fébrile (microbiologie)</term><term>Ressources en santé (utilisation)</term><term>Ressources en santé (économie)</term><term>Sujet immunodéprimé</term><term>Taux de survie</term><term>Voriconazole (usage thérapeutique)</term><term>Voriconazole (économie)</term><term>Échinocandines (usage thérapeutique)</term><term>Échinocandines (économie)</term><term>Économies</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Mannans</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Amphotericin B</term><term>Antifungal Agents</term><term>Deoxycholic Acid</term><term>Echinocandins</term><term>Voriconazole</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amphotericin B</term><term>Antifungal Agents</term><term>Deoxycholic Acid</term><term>Echinocandins</term><term>Voriconazole</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Mannanes</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Aspergillosis</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Aspergillose</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Aspergillosis</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Aspergillosis</term><term>Health Resources</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Aspergillus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Aspergillus</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Neutropénie fébrile</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Febrile Neutropenia</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Aspergillose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acide désoxycholique</term><term>Amphotéricine B</term><term>Antifongiques</term><term>Voriconazole</term><term>Échinocandines</term></keywords><keywords scheme="MESH" qualifier="utilisation" xml:lang="fr"><term>Ressources en santé</term></keywords><keywords scheme="MESH" qualifier="utilization" xml:lang="en"><term>Health Resources</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Acide désoxycholique</term><term>Amphotéricine B</term><term>Antifongiques</term><term>Aspergillose</term><term>Ressources en santé</term><term>Voriconazole</term><term>Échinocandines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cost Savings</term><term>Decision Trees</term><term>Drug Combinations</term><term>Health Care Costs</term><term>Humans</term><term>Immunocompromised Host</term><term>Lipopeptides</term><term>Survival Rate</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Arbres de décision</term><term>Association médicamenteuse</term><term>Coûts des soins de santé</term><term>Humains</term><term>Lipopeptides</term><term>Sujet immunodéprimé</term><term>Taux de survie</term><term>Économies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with persistent or recurrent neutropenic fevers at risk of invasive fungal disease (IFD) are treated empirically with antifungal therapy (AFT). Early treatment using a diagnostic-driven (DD) strategy may reduce clinical and economic burdens. We compared costs and outcomes of both strategies from a UK perspective.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>Canada</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Alsace (région administrative)</li><li>Caroline du Nord</li><li>Grand Est</li><li>Manitoba</li><li>Victoria (État)</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Melbourne</li><li>Paris</li><li>Strasbourg</li><li>Winnipeg</li></settlement><orgName><li>Université de Melbourne</li><li>Université du Manitoba</li></orgName></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Barnes, Rosemary" sort="Barnes, Rosemary" uniqKey="Barnes R" first="Rosemary" last="Barnes">Rosemary Barnes</name></noRegion></country><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Earnshaw, Stephanie" sort="Earnshaw, Stephanie" uniqKey="Earnshaw S" first="Stephanie" last="Earnshaw">Stephanie Earnshaw</name></region><name sortKey="Mcdade, Cheryl" sort="Mcdade, Cheryl" uniqKey="Mcdade C" first="Cheryl" last="Mcdade">Cheryl Mcdade</name><name sortKey="Schlamm, Haran" sort="Schlamm, Haran" uniqKey="Schlamm H" first="Haran" last="Schlamm">Haran Schlamm</name></country><country name="France"><region name="Grand Est"><name sortKey="Herbrecht, Raoul" sort="Herbrecht, Raoul" uniqKey="Herbrecht R" first="Raoul" last="Herbrecht">Raoul Herbrecht</name></region><name sortKey="Charbonneau, Claudie" sort="Charbonneau, Claudie" uniqKey="Charbonneau C" first="Claudie" last="Charbonneau">Claudie Charbonneau</name><name sortKey="Kantecki, Michal" sort="Kantecki, Michal" uniqKey="Kantecki M" first="Michal" last="Kantecki">Michal Kantecki</name><name sortKey="Weinstein, David" sort="Weinstein, David" uniqKey="Weinstein D" first="David" last="Weinstein">David Weinstein</name></country><country name="Australie"><noRegion><name sortKey="Morrissey, Orla" sort="Morrissey, Orla" uniqKey="Morrissey O" first="Orla" last="Morrissey">Orla Morrissey</name></noRegion><name sortKey="Slavin, Monica" sort="Slavin, Monica" uniqKey="Slavin M" first="Monica" last="Slavin">Monica Slavin</name></country><country name="Canada"><region name="Manitoba"><name sortKey="Bow, Eric" sort="Bow, Eric" uniqKey="Bow E" first="Eric" last="Bow">Eric Bow</name></region></country><country name="Belgique"><noRegion><name sortKey="Maertens, Johan" sort="Maertens, Johan" uniqKey="Maertens J" first="Johan" last="Maertens">Johan Maertens</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E82 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002E82 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25891805
|texte= Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25891805" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |